STOCK TITAN

Zoetis Inc. - ZTS STOCK NEWS

Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.

Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.

The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.

Rhea-AI Summary

Zoetis (NYSE: ZTS) will host a webcast and conference call to discuss its second quarter 2024 financial results on Tuesday, August 6, 2024, at 8:30 a.m. (ET). CEO Kristin Peck and CFO Wetteny Joseph will review the results and answer questions from financial analysts. The webcast will be accessible through the Zoetis investor website, with pre-registration information available now. A replay of the webcast will be available starting the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conference call conferences earnings
-
Rhea-AI Summary

Zoetis Foundation has announced a $3 million grant to the American Red Cross, to be used over six years for global disaster relief efforts. This grant will support the Annual Disaster Giving Program, aiding both domestic and international disaster response and preparedness. In addition, Zoetis has launched a consumer matching campaign with American Humane to support pets affected by natural disasters in the U.S.

Zoetis has a decade-long partnership with American Humane, focusing on animal safety in disaster situations, and they have contributed to the care of 1.3 million animals globally between 2021-2023. The collaboration includes operating emergency vehicles stocked with Zoetis pet medications and hosting pet preparedness clinics.

The Zoetis Foundation’s support aims to bolster the Red Cross' ability to respond to disasters and help communities prepare for future crises. This initiative is part of Zoetis' broader sustainability strategy, which has made significant impacts worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
Rhea-AI Summary

Zoetis released its 2023 Sustainability Report, highlighting advancements in its 'Driven to Care' strategy. Key achievements include:

1. Increasing volunteer work by 81% to 16,611 hours.

2. Supporting 28 initiatives with $8.3 million in grants across 19 countries.

3. Launching innovative diagnostics, vaccines, and parasiticides for livestock producers.

4. Utilizing over 30% renewable electricity with on-site solar arrays at seven facilities, aiming for 100% by 2030.

5. Replacing rabies vaccine packaging plastic with paperboard, reducing PVC use by 8.0 metric tons annually.

Zoetis invested $7 million in community programs, reaching 202,000 pet owners and impacting 91,000 animals. The company also received eight awards for fostering an inclusive culture and expanded its Leading@Zoetis program to over 2,000 leaders globally.

Zoetis aims to achieve carbon neutrality by 2030, reporting 32.6% renewable electricity use, completing 38 energy efficiency projects, and reducing Scope 1 and 2 emissions by 18.9% since 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
none
Rhea-AI Summary

The Board of Directors at Zoetis (NYSE: ZTS) has announced a dividend of $0.432 per share for the third quarter of 2024.

This dividend will be disbursed on September 4, 2024, to all shareholders of record as of July 18, 2024. The company continues its commitment to returning value to its shareholders through regular dividend payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
dividends earnings
-
Rhea-AI Summary

Zoetis (NYSE: ZTS) will attend the William Blair 44th Annual Growth Stock Conference on June 4, 2024.

Wetteny Joseph, Executive Vice President and CFO, will represent the company and answer analysts' questions. His presentation is scheduled for 2:40 p.m. CT.

Investors and interested parties can access the live audio webcast of the presentation via the Zoetis investor relations website. A replay will be available following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences
-
Rhea-AI Summary

Zoetis (NYSE: ZTS) will participate in the Stifel 2024 Jaws and Paws Conference on May 29, 2024. Kristin Peck, CEO, will represent the company and respond to analysts' questions. Her presentation is scheduled for 12:05 p.m. ET and will be available via a live audio webcast on the Zoetis investor website. A replay will also be accessible after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) reported a successful first quarter of 2024 with revenue of $2.2 billion, a 10% increase YoY. Net income was $599 million, or $1.31 per diluted share, up 9% and 10%, respectively. Adjusted net income was $634 million, or $1.38 per diluted share. The company updated its full-year 2024 revenue guidance to $9.050 - $9.200 billion, showing operational revenue growth of 8.5% to 10.5%. Zoetis continues to invest in innovation and growth, expanding product franchises globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
-
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) has entered into a definitive agreement with Phibro Animal Health (Nasdaq: PAHC), where the latter will acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products, and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. The portfolio, generating approximately $400 million in revenue in 2023, comprises more than 37 product lines sold in around 80 countries, spanning across six manufacturing sites. More than 300 Zoetis colleagues will transition to Phibro Animal Health. The divestiture allows Zoetis to focus its livestock investments in other areas, such as vaccine, biologic, and genetic programs. The acquisition is expected to boost Phibro Animal Health’s sales and profitability significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.81%
Tags
none
-
Rhea-AI Summary
The Zoetis Foundation is championing global veterinarian education, well-being, and livelihoods on World Veterinary Day and beyond by providing grant support to initiatives promoting veterinary education, mental well-being, and livelihoods. The Foundation has committed $18.7 million to advance opportunities for veterinarians and farmers worldwide, fund humanitarian relief efforts, and support colleague matching gifts. Key grantees include the American Association of Veterinary Medical Colleges, the Federation of Veterinarians of Europe, and the World Food Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Summary
Zoetis Inc. (NYSE: ZTS) appoints Gavin D.K. Hattersley, President and CEO of Molson Coors Beverage Company, to its Board of Directors. Hattersley brings global public company leadership and board experience, enhancing Zoetis' expansion in key markets. His appointment reflects Zoetis' commitment to innovation and customer-centric animal health solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
management

FAQ

What does Zoetis Inc. specialize in?

Zoetis Inc. specializes in medicines and vaccinations for pets and livestock, including anti-infectives, vaccines, parasiticides, diagnostics, and other health products.

Is Zoetis Inc. still part of Pfizer?

No, Zoetis Inc. became an independent company after Pfizer spun off its 83% interest.

What percentage of Zoetis' revenue comes from companion animals?

Nearly 65% of Zoetis' revenue comes from companion animal products such as those for dogs, horses, and cats.

Which segment contributes more to Zoetis' U.S. business?

Zoetis' U.S. business is heavily skewed toward companion animals.

How does Zoetis' international business differ from its U.S. business?

Internationally, Zoetis' business is slightly skewed towards production animals, unlike its U.S. business, which focuses more on companion animals.

What recent achievements has Zoetis Inc. accomplished?

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity.

What are Zoetis' current projects?

Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

What is Zoetis' market position in the industry?

Zoetis holds the largest market share in the animal health industry.

Does Zoetis have any strategic partnerships?

Yes, Zoetis has strategic partnerships to expand its market reach and foster innovation.

Where can I find the latest updates on Zoetis Inc.?

You can stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. on StockTitan and other financial news platforms.

Zoetis Inc.

NYSE:ZTS

ZTS Rankings

ZTS Stock Data

81.49B
456.30M
0.24%
95.77%
1.51%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PARSIPPANY